Xact Kapitalforvaltning’s Charles River Laboratories CRL Stock Holding History

Xact Kapitalforvaltning’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$1.03M	Hold	8,137	–	–	0.02%	497
2019 Q4	$1.24M	Hold	8,137	–	–	0.02%	543
2019 Q3	$1.08M	Hold	8,137	–	–	0.02%	546
2019 Q2	$1.16M	Hold	8,137	–	–	0.02%	525
2019 Q1	$1.18M	Hold	8,137	–	–	0.03%	521
2018 Q4	$921K	Buy	8,137 +500	+7%	+$62.6K	0.02%	574
2018 Q3	$1.03M	Hold	7,637	–	–	0.02%	572
2018 Q2	$857K	Buy	7,637 +1,600	+27%	+$173K	0.02%	635
2018 Q1	$644K	Buy	6,037 +1,500	+33%	+$162K	0.01%	702
2017 Q4	$497K	Buy	+4,537	New	+$494K	0.01%	682

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Xact Kapitalforvaltning's CRL Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Charles River Laboratories (CRL) position steady in Q1 2020 at 8,137 shares worth $1.03M. The position accounts for 0.02% of the portfolio, ranked #497.

Xact Kapitalforvaltning first reported a position in CRL in Q4 2017 and has held it in 10 quarters since. The position peaked at $1.24M in Q4 2019. 416 funds tracked by Wall St. Rank hold CRL as of Q1 2020.

Xact Kapitalforvaltning held 8,137 shares of Charles River Laboratories worth $1.03M as of Q1 2020.
Xact Kapitalforvaltning left its Charles River Laboratories share count unchanged in Q1 2020.
Charles River Laboratories made up 0.02% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #497 holding.
Xact Kapitalforvaltning first reported a position in Charles River Laboratories in Q4 2017 and has held it in 10 quarters since.
Xact Kapitalforvaltning's Charles River Laboratories position peaked at $1.24M in Q4 2019.
416 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.